Benitec, Inc. Release: Hepatitis C Trial To Proceed
Published: Jan 14, 2014
Sydney Australia, 14th January 2014: RNAi - based therapeutics company Benitec Biopharma Limited (ASX: BLT) today announced that the US Food and Drug Administration (FDA) has advised the Company that it may proceed with it s ‘f irst in man’ clinical trial for TT - 034, a ddRNAi - based therapeutic, designed to treat Hepatitis C with a single injection .
This follows the FDA’s review of Benitec’s Investigational New Drug (IND) application, which was filed on 6 December 2013.
Benitec Biopharma’s CEO and Managing Director, Peter French said, “We are very pleased with this outcome which establishes Benitec as a clinical stage company .”
For further information, please contact the persons outlined below, or visit the Benitec website at www.benitec.com .
Chief Business Officer
Tel: +61 (2) 9555 6986
l: +61 (2) 9237 2807
About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX - listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in - house and partnered therapeutic programs based on its patented ge ne - silencing technology, ddRNAi . Benitec is developing treatments for chronic and life - threatening human conditions such as Hepatitis C , Hepatitis B, wet age - related macular degeneration, cancer - associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs t owards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at www.benitec.com .
Help employers find you! Check out all the jobs and post your resume.